Recent Security Class Actions

REGENXBIO Inc. Common Stock (NASDAQ: RGNX)

Today is the last day to seek lead plaintiff status.

Company Name:REGENXBIO Inc. Common Stock
Stock Symbol:NASDAQ: RGNX
Class Period Start:02/09/2022
Class Period End (inclusive):01/27/2026
Filing Deadline:04/14/2026

The Complaint alleges that the Defendants provided investors with material information concerning REGENXBIO’s plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. Defendants’ statements included, among other things, REGENXBIO’s positive assertions of RGX-111’s future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study.

REGENXBIO Inc. Common Stock (NASDAQ: RGNX) Claim Form

This field is for validation purposes and should be left unchanged.
Name(Required)
Address